News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Evotec AG (EVTG.F): Results Of Pre-Clinical Studies Lead To Reduction In Revenues, Nevertheless Profitable And More Than EURO 90 M Cash For 2013 Confirmed


12/13/2013 9:09:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HAMBURG, Germany, Dec. 13, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it is adjusting its guidance regarding Group revenues.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
Evotec AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES